

Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)

Technology appraisal guidance

Published: 19 November 2025

www.nice.org.uk/guidance/ta1111

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years. This is because Boehringer Ingelheim did not provide an evidence submission. The company has confirmed that it does not intend to make a submission for the appraisal. The company considers that there is insufficient new evidence to provide a submission for this appraisal at this time.

Information

If NHS organisations wish to consider nintedanib for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-7327-9